PDCD1 and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment with TKI+PD-1 Ab also reduced human BC CML leukemic burden (mean: 40.01% vs 58.4%; P = 0.001) but did not change survival significantly (median: 61.5 vs 56 days, P = 0.125) compared to TKI alone (Fig. 7i).